Clinical Trial Details

Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine vs. placebo in patients with residual disease post-neoadjuvant chemotherapy

IRB Protocol Number

ACCRU BR-1701

Clinical Trial Categories

• Breast Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: Women over 18 years old, diagnosed with HER2 positive breast cancer stage T2 or greater OR N1 or greater for pre-registration. Registration occurs post curative breast surgery, any radiation, or chemotherapy with assessment of residual disease status.